1. Pink Sheet
  2. >>Product Reviews
  3. >>Approvals

FDA 2017 First Generics Approvals Retain India Imprint

 
• By Anju Ghangurde

Indian companies continued to have marked presence in list of first generics approved by US FDA in 2017; clearances include some limited competition drugs and complex products that are vital for Indian firms as they transition their portfolios away from 'plain vanilla' generics.

Approved
INDIAN FIRMS HAVE RECEIVED A SIGNIFICANT SHARE OF FIRST GENERIC APPROVALS FROM THE US FDA.

Indian firms accounted for over a quarter of the “first generics” approved by the US FDA in 2017. The approvals include some limited competition and complex products, reflecting, in part, ongoing efforts of small and big Indian companies that are recalibrating their portfolios towards these underpenetrated and more lucrative segments.

“First generics” represent the first approval by the FDA which permits a manufacturer to market a generic drug in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

Lerodalcibep And First Generic Palbociclib Among 10 New EMA Filings

 
• By Neena Brizmohun

Lerodalcibep and palbociclib are among the latest new drugs that the European Medicines Agency has started to review for potential EU marketing authorization.

EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 
• By Eliza Slawther

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.

Argentina Speeds Up Market Access Process

 
• By Francesca Bruce

Companies operating in Argentina may get their medicines to the market more quickly thanks to new updates to the medicines authorization system.

More from Product Reviews